Ning Zhao1, Yanjuan Liu1, Hongfeng Liang2, Xuejun Jiang1. 1. Department of E. N. T., The First Hospital Affiliated of China Medical University 155 Nanjing Bei Street, Shenyang 110001, China. 2. Department of E. N. T., The First Hospital Affiliated of Dalian Medical University 222 Zhongshan Road, Dalian 116013, China.
Abstract
OBJECT: To determine the potential of bone marrow-derived mesenchymal stem cells (BMSCs) for immunomodulatory mechanism in mice model of allergic rhinitis (AR). METHODS: BMSCs were isolated and the surface markers and stemness were analyzed. The effect of BMSCs was evaluated in BALB/c mice that were randomly divided into three groups (control group, ovalbumin (OVA) group, OVA+BMSCs group). BMSCs were administered intravenously to OVA sensitized mice on days 1, 7, 14 and 21, and subsequent OVA challenge was conducted daily from days 22 to 35. Several parameters of allergic inflammation were assessed. RESULTS: Mesenchymal stem cells can be successfully isolated from bone marrow of mice. Intravenous injection of BMSCs significantly reduced allergic symptoms, eosinophil infiltration, OVA-specific immunoglobulin E (IgE), T-helper 2 (Th2) cytokine profile (interleukin (IL)-4, IL-5 and IL-13) and regulatory cytokines (IL-10). In addition, level of Th1 (IFN-γ) was significantly increased. CONCLUSION: Administration of BMSCs effectively reduced allergic symptoms and inflammatory parameters in the mice model of AR. BMSCs treatment is potentially an alternative therapeutic modality in AR.
OBJECT: To determine the potential of bone marrow-derived mesenchymal stem cells (BMSCs) for immunomodulatory mechanism in mice model of allergic rhinitis (AR). METHODS: BMSCs were isolated and the surface markers and stemness were analyzed. The effect of BMSCs was evaluated in BALB/c mice that were randomly divided into three groups (control group, ovalbumin (OVA) group, OVA+BMSCs group). BMSCs were administered intravenously to OVA sensitized mice on days 1, 7, 14 and 21, and subsequent OVA challenge was conducted daily from days 22 to 35. Several parameters of allergic inflammation were assessed. RESULTS: Mesenchymal stem cells can be successfully isolated from bone marrow of mice. Intravenous injection of BMSCs significantly reduced allergic symptoms, eosinophil infiltration, OVA-specific immunoglobulin E (IgE), T-helper 2 (Th2) cytokine profile (interleukin (IL)-4, IL-5 and IL-13) and regulatory cytokines (IL-10). In addition, level of Th1 (IFN-γ) was significantly increased. CONCLUSION: Administration of BMSCs effectively reduced allergic symptoms and inflammatory parameters in the mice model of AR. BMSCs treatment is potentially an alternative therapeutic modality in AR.
Authors: Hiroko Saito; Koichiro Matsumoto; Avram E Denburg; Lynn Crawford; Russ Ellis; Mark D Inman; Roma Sehmi; Kiyoshi Takatsu; Klaus I Matthaei; Judah A Denburg Journal: J Immunol Date: 2002-03-15 Impact factor: 5.422
Authors: Victor C Huber; Raelene M McKeon; Martha N Brackin; Laura A Miller; Rachael Keating; Scott A Brown; Natalia Makarova; Daniel R Perez; Gene H Macdonald; Jonathan A McCullers Journal: Clin Vaccine Immunol Date: 2006-09